Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction.
Takuya ShoGoki SudaAtsushi NagasakaYoshiya YamamotoKen FuruyaKenichi KumagaiMinoru UebayashiKatsumi TerashitaTomoe KobayashiIzumi TsunematsuManabu OnoderaTakashi MeguroMegumi KimuraJun ItoMachiko UmemuraTakaaki IzumiNaoki KawagishiMasatsugu OharaYuji OnoMasato NakaiMitsuteru NatsuizakaKenichi MorikawaKoji OgawaNaoya Sakamotonull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)
Sofosbuvir and RBV therapy is highly effective and safe for genotype 2 HCV-infected Japanese patients. However, attention should be paid to baseline renal function when SOF- and RBV-containing regimens are used for patients with renal dysfunction.